作者
Yi Zhang,Miso Park,Lucy Ghoda,Dandan Zhao,Melissa Valerio,Ebtesam Nafie,Asaul Gonzalez,Kévin Ly,Bea Parcutela,Hyeran Choi,Xiaolan Gong,Chen Fang,Kaito Harada,Zhenhua Chen,Le Xuan Truong Nguyen,Flavia Pichiorri,Jianjun Chen,Joo Y. Song,Stephen J. Forman,Idoroenyi Amanam,Bin Zhang,Jie Jin,John C. Williams,Guido Marcucci
摘要
The interleukin-1 receptor accessory protein (IL1RAP) is highly expressed on acute myeloid leukemia (AML) bulk blasts and leukemic stem cells (LSCs), but not on normal hematopoietic stem cells (HSCs), providing an opportunity to target and eliminate the disease, while sparing normal hematopoiesis. Herein, we report the activity of BIF002, a novel anti-IL1RAP/CD3 T cell engager (TCE) in AML.